CNC · Q2 2025 Earnings
BearishCentene Corporation
Reported July 1, 2025
30-second summary
Centene reported a Q2 FY2025 adjusted loss of $0.16/share and slashed full-year adjusted EPS guidance to approximately $1.75 from $7.25 — a $5.50 cut driven by $2.4B of full-year marketplace earnings pressure (risk adjustment plus morbidity-driven utilization, up from the $1.8B flagged on July 1 using 72% of membership data) and an unacceptable 94.9% Medicaid HBR. Management framed the miss as fixable through 2026 repricing of 100% of the marketplace book and Medicaid rate advocacy, but the magnitude of the cut, the breadth across two of three core lines, and the defensive tone ("disappointed," "frustrated," "unacceptable") mark this as a structural reset, not a one-quarter stumble. The bull case now hinges entirely on execution over the next 4–6 quarters.
Guidance
Prior quarter data unavailable — comparison not possible.
Management tone
The contrast with Centene's typical operationally-detailed, cautiously-optimistic posture is sharp. This call read as damage control.
Management acknowledged the miss with unusually direct language — "We are disappointed by this performance and frustrated to have fallen short of the financial goals we set at the start of the year." That accountability framing is rare in managed care, and it signals the leadership team understood that hedging would have destroyed remaining credibility after the July 1 pre-announcement.
The marketplace problem grew between July 1 and this print. On July 1, with 72% of membership data, Centene flagged $1.8B of earnings pressure; on this call, with 100% of the data, that number became $2.4B — a 33% expansion. Management's framing shifted from "contained issue with incomplete data" to "Ambetter was underpriced for this morbidity shift." That is not a refinement; it is a re-diagnosis.
The Medicaid commentary marks a clear break from prior posture. Q2 FY2025's 94.9% HBR was called "unanticipated and unacceptable" — words that imply the internal forecasting process failed, not just that the environment deteriorated. Combined with the disclosure that only one-third of health plans are outperforming HBR targets, the picture is of broad-based underperformance rather than a few problem states (despite Florida's 40bp contribution).
The reassurance language — "There is substantial future earnings power in this revenue base… This is fixable" — is doing heavy lifting. It attempts to reframe a $5.50 EPS cut as a temporary operational challenge. Investors will judge that framing against the 4–6 quarter recovery timeline management laid out, not against management's confidence today.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
AJ Wright · UBS
Drill down on public exchange risk adjustment true-off and whether management thought program integrity impacts applied to them but not broader market. Also ask about 2026 repricing assumptions, target margins for exchanges, and implications for disenrollment.
Management explained that they initially underestimated the breadth of low/non-utilizing member departures from program integrity measures. They clarified that markets experienced different morbidity impacts—some won't face full impact until 2026 when measures are applied universally. Management expects to reprice 100% of marketplace book for profitability in 2026, with target margins to be disclosed after seeing imp1A file in September. They assume law of the land with expired enhanced APTCs.
Justin Lake · Wolf Research
Confirm expectation of higher earnings in 2026. Question the 140 basis points of Medicaid MLR improvement implied in H2 guidance versus peers' assumptions of deterioration, and whether Q2 reported figures contain negative entry year development.
Management confirmed expectation of margin and earnings improvement across all three lines in 2026. On Medicaid, they detailed that Q2's 94.9% MLR was driven by trend acceleration in behavioral health (50%, primarily ABA), home health (30%, HCBS), and high cost drugs. Concentrated in a small number of states (Florida alone 40bps). Management is pulling multiple levers including utilization management, clinical policy guidelines, fraud/waste/abuse stamping, and rate advocacy, with about one-third of health plans outperforming HBR targets.
David Wendley · Jeffries
Ask about Wakely data on implied market membership trends and attrition; what is current market size, what assumptions on further attrition over balance of 2025, and potential morbidity shift implications.
Management stated Wakely data showed overall market growth of 0.5% vs. prior DMS expectations, with actual market contraction during 2025 open enrollment and continued month-over-month contraction. Company is at 5.9M members today, expecting to end year at 5.4M. FTR-driven attrition expected in summer/August. Expects further 2026 attrition with open enrollment, estimating disenrollment range of 15-50% depending on APTC status, with actual impact likely in middle of that range accounting for 2025 pull-forward effect.
Lance Wilkes · Bernstein
Discuss strategy for addressing risk adjustment payable/receivable position in 2026 and beyond—will company reposition for lower payable or accept higher payable status, and what are other strategic considerations around membership and profitability.
Management stated they are being thoughtful about macro dynamics in each market and taking a margin-over-membership approach in 2026 repricing. They are considering product tweaks, network partner changes, and market presence adjustments. Long-term strategy focuses on optimizing portfolios for sustainable margins. On payability dynamics, management emphasized leveraging scale to drive transparency by making demographic data available earlier post-enrollment and working with CMS to lock down policy changes before pricing deadlines to improve market stability.
Kevin Fishback · Bank of America
Clarify Medicaid margin recovery timeline—does 'meaningful progress over 12-18 months' mean no return to target margins in 2027? Address whether cost trend and risk pool changes will create additional headwinds for margin recovery.
Management indicated recovery is 'when, not if' over next couple quarters through state rate discussions and leverage of actuarial data. They acknowledged future risk pool shifts from OB-3 provisions (work requirements, six-month verifications) will cause member losses, but are smarter now about accounting for that impact based on redeterminations experience. Stated confidence in improving margins through 4-6 quarters into 2027 and beyond, while being thoughtful about not overshooting. Highlighted states are increasingly using mid-year rate cycles for real-time trend assessment, which company is advocating for.
What to watch into next quarter
Marketplace 2026 target margins — management committed to disclose after the September imp1a file. Whether they target the prior 5–7.5% range or signal a structurally lower range will define the 2026 earnings reset
Medicaid HBR trajectory toward the ~93.5% H2 guide — Q3 FY2025 print will be the first test of whether the implied 140bp improvement is achievable; failure pushes FY EPS toward the $1.25 downside scenario management volunteered
2026 marketplace membership disclosure — watch whether early indicators support the midpoint of the 15–50% disenrollment range or skew toward the upper end as enhanced APTCs expire
Share of health plans outperforming HBR targets — currently one-third; movement of this share is the cleanest single signal on Medicaid remediation progress
Capital position and liquidity — recurring analyst question this quarter; expect tighter disclosure on subsidiary support capacity and any buyback pause given the EPS reset
Sources
- Centene Q2 FY2025 earnings call transcript (management prepared remarks and Q&A)
- Centene pre-announcement disclosure, July 1, 2025 (referenced on the call)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.